UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

Blood, 2018-04, Vol.131 (17), p.1910-1919

2018

Volltextzugriff (PDF)

Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results

Journal of allergy and clinical immunology, 2022-03, Vol.149 (3), p.977-987.e14

2022

Volltextzugriff (PDF)

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

The Lancet (British edition), 2021-06, Vol.397 (10290), p.2151-2168

2021

Volltextzugriff (PDF)

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2021-06, Vol.397 (10290), p.2169-2181

2021

Volltextzugriff (PDF)

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial

The Lancet (British edition), 2019-12, Vol.394 (10214), p.2108-2117

2019

Volltextzugriff (PDF)

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial

JAMA dermatology (Chicago, Ill.), 2021-09, Vol.157 (9), p.1047

2021

Volltextzugriff (PDF)

Tetramers reveal IL-17–secreting CD4⁺ T cells that are specific for U1-70 in lupus and mixed connective tissue disease

Proceedings of the National Academy of Sciences - PNAS, 2015-03, Vol.112 (10), p.3044-3049

2015

Volltextzugriff (PDF)

Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials

JAMA dermatology (Chicago, Ill.), 2022-04, Vol.158 (4), p.404

2022

Volltextzugriff (PDF)

IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice

The Journal of clinical investigation, 2008-04, Vol.118 (4), p.1417-1426

2008

Volltextzugriff (PDF)

Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One‐Year Results of a Double‐Blind, Placebo‐Controlled Study and Open‐Label Extension

Arthritis & rheumatology (Hoboken, N.J.), 2022-01, Vol.74 (1), p.70-80

2022

Volltextzugriff (PDF)

Population pharmacokinetic and exposure-response modelling to inform upadacitinib dose selection in adolescent and adult patients with atopic dermatitis

British journal of clinical pharmacology, 2023-10, Vol.89 (10), p.3139-3151

2023

Volltextzugriff (PDF)

Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies

Journal of allergy and clinical immunology, 2023-01, Vol.151 (1), p.172-181

2023

Volltextzugriff (PDF)

Pharmacokinetics, Safety, Tolerability, and Exploratory Efficacy of Upadacitinib in Children with Severe Atopic Dermatitis

Clinical therapeutics, 2024-10, Vol.46 (10), p.733-741

2024

Volltextzugriff (PDF)

A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis

JAAD international, 2022-03, Vol.6, p.27-36

2022

Volltextzugriff (PDF)

Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials

British journal of haematology, 2018-08, Vol.182 (4), p.504-512

2018

Volltextzugriff (PDF)

Generic versus disease-specific measures of health-related quality of life in systemic lupus erythematosus

Journal of rheumatology, 2011-09, Vol.38 (9), p.1821-1823

2011

Volltextzugriff (PDF)

Measuring outcomes in systemic lupus erythematosus clinical trials

Expert review of pharmacoeconomics & outcomes research, 2011-08, Vol.11 (4), p.455-468

2011

Volltextzugriff (PDF)

Natural Killer Cells From Children With Type 1 Diabetes Have Defects in NKG2D-Dependent Function and Signaling

Diabetes (New York, N.Y.), 2011-03, Vol.60 (3), p.857-866

2011

Volltextzugriff (PDF)

Development of Th17‐Associated Interstitial Kidney Inflammation in Lupus‐Prone Mice Lacking the Gene Encoding STAT‐1

Arthritis & rheumatology (Hoboken, N.J.), 2016-05, Vol.68 (5), p.1233-1244

2016

Volltextzugriff (PDF)

Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials

JAMA oncology, 2018-05, Vol.4 (5), p.712

2018

Volltextzugriff (PDF)

Active and latent tuberculosis in patients with systemic lupus erythematosus living in the United States

Journal of clinical rheumatology, 2009-08, Vol.15 (5), p.226-229

2009

Volltextzugriff (PDF)

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

The New England journal of medicine, 2014-07, Vol.371 (3), p.213-223

2014

Volltextzugriff (PDF)

528 - Rapid skin clearance and itch improvement with upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: results from a phase 3b head-to-head clinical trial (Heads Up)

British journal of dermatology (1951), 2024-02, Vol.190 (Supplement_2), p.ii30-ii31

2024

Volltextzugriff (PDF)

Abstract CT290: Ibrutinib-rituximab versus placebo-rituximab for first-line treatment of follicular lymphoma: PERSPECTIVE, a randomized phase 3 study

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT290-CT290

2020

Volltextzugriff (PDF)

1 – 25 von 43

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(42)
Berichte
(1)

Sprache

Englisch
(43)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial

Tetramers reveal IL-17–secreting CD4⁺ T cells that are specific for U1-70 in lupus and mixed connective tissue disease

Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials

IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice

Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One‐Year Results of a Double‐Blind, Placebo‐Controlled Study and Open‐Label Extension

Population pharmacokinetic and exposure-response modelling to inform upadacitinib dose selection in adolescent and adult patients with atopic dermatitis

Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies

Pharmacokinetics, Safety, Tolerability, and Exploratory Efficacy of Upadacitinib in Children with Severe Atopic Dermatitis

A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis

Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials

Generic versus disease-specific measures of health-related quality of life in systemic lupus erythematosus

Measuring outcomes in systemic lupus erythematosus clinical trials

Natural Killer Cells From Children With Type 1 Diabetes Have Defects in NKG2D-Dependent Function and Signaling

Development of Th17‐Associated Interstitial Kidney Inflammation in Lupus‐Prone Mice Lacking the Gene Encoding STAT‐1

Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials

Active and latent tuberculosis in patients with systemic lupus erythematosus living in the United States

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

528 - Rapid skin clearance and itch improvement with upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: results from a phase 3b head-to-head clinical trial (Heads Up)

Abstract CT290: Ibrutinib-rituximab versus placebo-rituximab for first-line treatment of follicular lymphoma: PERSPECTIVE, a randomized phase 3 study

Suchergebnisse filtern